Xcout IntelCan B Corp
Nascent Pharma Holdings, Inc. is primarily engaged in both protecting and bringing to market intellectual property pertaining to cannabis. Beyond this, the company also manufactures superfood beverage mixes, which are marketed under its "Longevity" brand. Established in 2005 and headquartered in Hicksville, New York, the firm previously operated as Can B Corp. and is slated to officially adopt the Nascent Pharma Holdings, Inc. name in September 2025.
Subscribe to see Can B Corp’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Can B Corp at a glance
Can B Corp is a biotech company headquartered in United States. It has raised at least $3M across the 2 funding rounds on record. Its most recent funding round raised $2.8M in December 2020. Xcout tracks 11 named people at Can B Corp, including Marco Alfonsi (Chairman & Chief Executive Officer).
Can B Corp leadership
- Marco AlfonsiChairman & Chief Executive Officer
- Pasquale FerroPresident of Pure Health Products LLC
- Steven ApolantPresident of Green Grow Farms, Inc.
- Stanley L. TeepleChief Financial Officer, Secretary & Director
- Greg PartinChief Information Officer
- Andrew W. HoltmeyerVice President of Business Development
5 more named people on record for Can B Corp, with roles, board committees and tenure — see the full roster →
Can B Corp funding rounds
At least $3M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $2.8M | — | |
| SEC Form D filing | $225,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Can B Corp competitors
A few of Can B Corp's closest competitors — see the full list of competitors and alternatives →
NeuroNascent, Inc. is a privately-held biotechnology and pharmaceutical corporation headquartered in Clarksville, Maryland, focused on developing treatments for diseases such as Alzheimer's and Down syndrome.
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
PsyRX CNS Bio-Tech Ltd is dedicated to developing cannabinoid-based pharmaceuticals and healthcare products. Its portfolio encompasses drugs targeting diverse medical conditions, personalized cannabinoid formulations, and CBD-infused skincare along with food supplements. Established in 2019, the company, formerly known as Cannabotech LTD, is headquartered in Rishon LeZion, Israel.
Cambrian BioPharma, Inc. is a biotechnology company headquartered in New York, United States, focused on developing therapeutics to extend human healthspan.
International Bioceutical Co., LLC operates as a cannabinoid life sciences company that manufactures and supplies EU-GMP certified active pharmaceutical ingredients (APIs). The company serves pharmaceutical companies, nutraceutical brands, and animal health organizations worldwide by providing cannabinoid-based ingredients and product development support for human and veterinary use.
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer. Another prominent candidate is CUBT906, a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to eradicate them by halting their growth and spread. Additionally, the company is advancing a reformulated Metformin for the management of degenerative eye disorders. Curative Biotechnology has entered into a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. to further advance IMT504, specifically for addressing advanced rabies and as a component of a COVID-19 vaccine. Previously known as Connectyx Technologies Holdings Group, Inc., the company adopted its current name, Curative Biotechnology, Inc., in November 2020. Established in 1995, the company maintains its headquarters in Boca Raton, Florida.
Get Can B Corp's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Can B Corp in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access